| Literature DB >> 16503141 |
Ester Muraglia1, Olaf D Kinzel, Ralph Laufer, Michael D Miller, Gregory Moyer, Vandna Munshi, Federica Orvieto, Maria Cecilia Palumbi, Giovanna Pescatore, Michael Rowley, Peter D Williams, Vincenzo Summa.
Abstract
A series of aryltetrazolylacetanilides was synthesized and evaluated as HIV-1 non-nucleoside reverse transcriptase inhibitors on wild-type virus and on the clinically relevant K103N mutant strain. Extensive SAR investigation led to potent compounds, with nanomolar activity on K103N, and orally bioavailable in rats.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16503141 DOI： 10.1016/j.bmcl.2006.02.024
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823